Evidence map›Paper›PMID 34200749›Full record

ArticleBiomedicines2021

The NHance

Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Philippe Barthélémy, Christophe Borg, Keunchil Park, Do-Youn Oh, Sang-We Kim, Natalie De Jonge, Valérie Hanssens and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. MET Oncogene Targeting for Cancer Immunotherapy.International journal of molecular sciences · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 5 countries.

Philippe AftimosMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Christian RolfoUniversity Hospital Antwerp, 2650 Edegem, Belgium.
Sylvie RotteyUniversity Hospital Ghent, 9000 Ghent, Belgium.
Philippe BarthélémyMedical Oncology Unit, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.ORCID 0000-0003-3917-0579
Christophe BorgMedical Oncology Department, University Hospital of Besançon, CEDEX, 25000 Besançon, France.
Keunchil ParkSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Do-Youn OhSeoul National University Hospital, Seoul 03080, Korea.
Sang-We KimAsan Medical Center, Department of Oncology, University of Ulsan College of Medicine, Seoul 05505, Korea.
Natalie De JongeArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Valérie HanssensArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Karen ZwanenpoelUniversity Hospital Antwerp, 2650 Edegem, Belgium.ORCID 0000-0001-9122-0639
Carla MolthoffDepartment of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, 1012 Amsterdam, The Netherlands.
Daniëlle VugtsDepartment of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, 1012 Amsterdam, The Netherlands.
Torsten DreierArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Peter VerheesenArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Guus A M S van DongenDepartment of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, 1012 Amsterdam, The Netherlands.
Julie JacobsArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Luc Van RompaeyArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Anna HultbergArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Paolo MichieliAgomAb Therapeutics NV, 9000 Ghent, Belgium.
Patrick PauwelsUniversity Hospital Antwerp, 2650 Edegem, Belgium.
Samson FungArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Alain ThibaultArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Hans de HaardArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Nicolas LeupinArgenx BV, Industriepark Zwijnaarde 7, 9052 Ghent, Belgium.
Ahmad AwadaMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Ablynx (Belgium) · BEAmsterdam UMC Location Vrije Universiteit Amsterdam · NLAntwerp University Hospital · BEUniversité Libre de Bruxelles · BECentre Hospitalier Universitaire de Besançon · FRGhent University Hospital · BEHôpitaux Universitaires de Strasbourg · FRSamsung Medical Center · KRSeoul National University Hospital · KRUlsan College · KRUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulation of MET signaling has been implicated in tumorigenesis and metastasis. ARGX-111 combines complete blockade of this pathway with enhanced tumor cell killing and was investigated in 24 patients with MET-positive advanced cancers in a phase 1b study at four dose levels (0.3-10 mg/kg). ARGX-111 was well tolerated up to 3 mg/kg (MTD). Anti-tumor activity was observed in nearly half of the patients (46%) with a mean duration of treatment of 12 weeks. NHance

Indexed as

18F-FDG-PET/CTantibodycancerMET

Identifiers

PMID34200749
PMCPMC8229762
OpenAlexW3171585916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.